MPS Completes Acquisition of HighWire Press to Accelerate Platform Business
1.7.2020 20:30:00 EEST | Business Wire | Press release
MPS Limited (MPS), a leading provider of content, learning, and platform solutions, has announced today that they have completed the acquisition of HighWire Press. HighWire has long been an industry thought leader and has championed many of the digital standards and initiatives that have shaped modern scholarly publishing.
MPS and HighWire share an ethos of embedding flexibility into publishing solutions through strategic partner programs and have grown and evolved their respective businesses organically, through third-party integrations, and selective acquisitions.
The combination presents a significant opportunity for MPS’ and Highwire’s customers. Increased resources, more comprehensive platform offerings, and a broader partner and distribution network are just some of the benefits.
“The acquisition of HighWire further deepens our commitment to the Academic/STM community, whom we were founded to serve back in 1970,” said Rahul Arora, CEO and Managing Director of MPS Limited. “We will further invest, build, and grow HighWire to advance global discovery, research, and innovation, which aligns with our overarching mission of Making Learning Smarter.”
“In the year that HighWire celebrates its 25th anniversary and MPS its 50th, we are excited to draw upon that wealth of knowledge to continue to shape the future of digital content,” said Tim Bacci, CEO of HighWire. “There is clear alignment with our core company values, and we are looking forward to leveraging the synergies as a result of our collective product suites that will prove beneficial to customers.”
About MPS Limited
MPS was established as a subsidiary of Macmillan Limited in 1970 to change the way the world learns. After a change of majority stake in 2011-12 and with an entrepreneurial mindset, MPS developed significant momentum as a result of consistent reinvestment in the business and six acquisitions in six years; the first five were acquisitions of scale while the sixth was an acquisition of scope.
MPS now provides platform, learning, and content solutions and is a global partner to the world’s leading enterprises, publishers, learning companies, and content aggregators. MPS is listed on major Indian stock exchanges; nearly 2,500 associates power MPS across seven development centers in India, two subsidiaries in Europe, and five client offices in the US. MPS has been at the forefront of market changes, introducing new ways of learning and driving impact from each learning experience through engaging content and advanced platforms.
About HighWire
HighWire is an industry-leading global provider of digital publishing tools and platform solutions across all aspects of the publishing life cycle, including content management and hosting, e-commerce, analytics, access and identity management, manuscript submission and tracking.
HighWire was born out of Stanford University, shaped the early stages of digital scholarly publishing, and is now celebrating its 25th year since it was founded. This combination of deep domain publishing and academic expertise makes HighWire the technology partner of choice for the leading global commercial and academic publishers.
For more information, please visit highwirepress.com and follow us on Twitter, LinkedIn, and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200701005809/en/
Contact information
Natalie Guest
Marketing Manager
nguest@highwirepress.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom